Palifermin use in patients , out of clinical investigation, which are receiving chemioterapic therapy with staminal cells to reduce severuty and incidence of mucositis. - ND

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001923-20-IT

Enrollment

Registered

2007-03-01

Start date

2006-04-27

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mucositis MedDRA version: 9.1 Level: LLT Classification code 10028128 Term: Mucositis management

Interventions

Trade Name: Kepivance Pharmaceutical Form: Powder for infusion* Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age 18 ;paz. with staminal cells trasplantation after mieloablative conditioning procedures; patients affected by non Hodking s linfoma,Hodcking disease, mieloid leucemia,leucemia mieloide acuta, linfoblastic acute leucemia , chronic linphatic leucemia or multiple mieloma Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: hospitalization and myocardial infarction 30 days before the start of the trial; inadeguate contraception;nursing.

Design outcomes

Primary

Measure	Time frame
Main Objective: incidence and time reduction of severe mucositis;Secondary Objective: incidence and time reduction of severe mucositis;Primary end point(s): x	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026